CCCC – c4 therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
C4 Therapeutics, Inc. (NASDAQ: CCCC) is now covered by analysts at Stephens. They set an "equal weight" rating and a $4.00 price target on the stock.
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
Form 4 C4 Therapeutics, Inc. For: Nov 19 Filed by: Hoerter Steven L.
Form 3 C4 Therapeutics, Inc. For: Nov 19 Filed by: Hoerter Steven L.
Form 8-K C4 Therapeutics, Inc. For: Nov 20
Form 144 C4 Therapeutics, Inc. Filed by: Salter Malcolm
Form 424B3 C4 Therapeutics, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.